公开(公告)号：US20200341014A1

公开(公告)日：2020-10-29

申请号：US16078557

申请日：2017-03-16

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Mai Kimura ,  Sotaro Motoi ,  Takashi Obara ,  Katsuhiro Moriya ,  Hideaki Ogasawara ,  Yoshihisa Arita ,  Tetsu Kawano

IPC: G01N33/92 ,  C12Q1/6883

Abstract: The present invention provides a method for evaluating the pharmacological action of HGF that utilizes a PD marker in which fluctuation is recognized by administration of hepatocyte growth factor (HGF) in a broader range of subjects. A method for evaluating the pharmacodynamic action of HGF is provided. The aforementioned evaluation method is characterized in that it comprises a step of measuring the ApoA4 level in a biological sample collected from a test subject who was administered HGF. According to the present invention, a kit for evaluating the pharmacodynamic action of HGF comprising an anti-ApoA4 antibody is further provided.

公开(公告)号：US10526603B1

公开(公告)日：2020-01-07

申请号：US16354916

申请日：2019-03-15

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yuta Suzuki ,  Sotaro Motoi ,  Yoshinori Takahashi ,  Kazuhiro Tahara

IPC: C12N15/113 ,  A61P7/00

Abstract: Provided is a novel double-stranded ribonucleic acid for suppressing expression of complement C5. A double-stranded ribonucleic acid comprising a combination of sense strand and antisense strand, wherein the combination of the sense strand and antisense strand are selected from the group consisting of combinations: SEQ ID NO: 13/14, SEQ ID NO: 159/160, SEQ ID NO: 115/116, SEQ ID NO: 117/118, SEQ ID NO: 119/120, SEQ ID NO: 121/122, SEQ ID NO: 123/124, SEQ ID NO: 125/126, SEQ ID NO: 127/128, SEQ ID NO: 129/130, SEQ ID NO: 131/132, SEQ ID NO: 133/134, SEQ ID NO: 137/138, SEQ ID NO: 139/140, SEQ ID NO: 141/142, SEQ ID NO: 143/144, SEQ ID NO: 145/146, SEQ ID NO: 147/148, SEQ ID NO: 149/150, SEQ ID NO: 151/152, and SEQ ID NO: 153/154.